5-Cyclopropylpyridin-3-ylboronic acid, 95.0%, 250mg

5-HYDROXYMETHYL-2'-DEOXYURIDINE, 250mg

Microliter syringe GASTIGHT® series 1700 Point type 2, 25 µl, 1702 RN, 1 piece

(E)-3-(dimethylamino)-2-phenylmethoxyprop-2-enal, 97%, 250mg

4-Methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile, 97%, 25g

tert-Butyl ((1H-indol-5-yl)methyl)carbamate, 95%, 1g

3-Phenoxyphenol, 95.0%, 25g

3-[2,6-Bis(1-methylethyl)phenyl]-5,6,7,8-tetrahydro-4H-cycloheptathiazolium Perchlorate>95.0%(HPLC)(T)1g

3-Bromo-6-hydrazinyl-2-methylpyridine, 95.0%, 1g

5-Methylpyridine-3-boronic acid, 95.0%, 5g

(2R,5R)-1-[2-(1,3-Dioxolan-2-yl)phenyl]-2,5-dimethylphospholane, 97%, 100mg

1-(trans-4-Butylcyclohexyl)-4-iodobenzene, 99.5%, 10g

5-Methyl-3-(pyrimidin-2-yl)-1,2,4-oxadiazole, 250mg